Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Bayer has licensed an experimental heart-disease program from Dewpoint Therapeutics, marking the first option exercise under a research collaboration the…
Bayer AG has exercised its first option to license a heart-disease program under a 2019 research collaboration with Dewpoint Therapeutics Inc., the…
Dewpoint laid off ~70% of its 130 employees, closed its Frankfurt and Dresden sites, and refocused on oncology lead DPTx3186; the Bayer dilated cardiomyopathy…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Bayer exercised its first option under a 2019 multi-program research collaboration with Dewpoint Therapeutics (announced Oct 24, 2024) to license a precision-medicine program for genetic dilated cardiomyopathy (DCM) — a severe form driven by disease-associated biomolecular condensates, with early-onset heart failure and life-threatening arrhythmias. Per both companies' releases, Dewpoint is eligible for an upfront payment plus development and commercial milestones totaling an estimated $424 million, excluding royalties; the upfront/milestone split was not disclosed. The program pairs Dewpoint's biomolecular-condensate platform with Bayer's small-molecule R&D. In August 2025 Dewpoint restructured sharply — cutting ~70% of its ~130 staff, closing its Frankfurt and Dresden sites, and refocusing on oncology lead DPTx3186 (beta-catenin inhibitor) — but the Bayer-partnered DCM program was explicitly retained and remains active (preclinical/Phase 1-2) on Dewpoint's pipeline, underscoring its standing as a funded, partner-owned asset.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bayer AG / Dewpoint Therapeutics Inc. (this deal) | 2024 | $424M | — |
| Bayer AG / Schering AG | 2006 | $21.5B | 79 |
| Bayer AG / BlueRock Therapeutics | 2002 | $600M | 79 |
| Bayer AG / Merck & Co., Inc. | 2014 | $14.2B | 71 |
| Bayer AG / Schering AG (residual squeeze-out) | 2007 | $985M | 69 |
| Bayer AG / Arvinas, Inc. | 2019 | $1.0B | 59 |
| Bayer AG / Merck & Co. Inc. | 2014 | $14.2B | 56 |
← Browse all deals · How we score deals
More: 2024 deals · Bayer AG deals · Cardiovascular deals